Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations

J Wang, B Wang, H Chu, Y Yao - OncoTargets and therapy, 2016 - Taylor & Francis
Identifying activating EGFR mutations is a useful predictive strategy that helps select a
population of advanced non-small-cell lung cancer (NSCLC) patients for treatment with …
被引用次数：148 相关文章

Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations

J Wang, B Wang, H Chu, Y Yao - OncoTargets and Therapy, 2016 - search.proquest.com
Identifying activating EGFR mutations is a useful predictive strategy that helps select a
population of advanced non-small-cell lung cancer (NSCLC) patients for treatment with …

Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations

J Wang, B Wang, H Chu, Y Yao - OncoTargets and …, 2016 - pubmed.ncbi.nlm.nih.gov
Identifying activating EGFR mutations is a useful predictive strategy that helps select a
population of advanced non-small-cell lung cancer (NSCLC) patients for treatment with …

[引用][C] Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations

J Wang, B Wang, H Chu, Y Yao - OncoTargets and Therapy, 2016 - cir.nii.ac.jp
Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer
with activating EGFR mutations | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …

Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations

J Wang, B Wang, H Chu, Y Yao - OncoTargets and Therapy, 2016 - dovepress.com
Identifying activating EGFR mutations is a useful predictive strategy that helps select a
population of advanced non-small-cell lung cancer (NSCLC) patients for treatment with …

Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations

J Wang, B Wang, H Chu, Y Yao - OncoTargets and Therapy, 2016 - go.gale.com
Identifying activating EGFR mutations is a useful predictive strategy that helps select a
population of advanced non-small-cell lung cancer (NSCLC) patients for treatment with …
[HTML] nih.gov

[HTML][HTML] Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations

J Wang, B Wang, H Chu, Y Yao - OncoTargets and therapy, 2016 - ncbi.nlm.nih.gov
Identifying activating EGFR mutations is a useful predictive strategy that helps select a
population of advanced non-small-cell lung cancer (NSCLC) patients for treatment with …

Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations.

J Wang, B Wang, H Chu, Y Yao - Oncotargets and Therapy, 2016 - europepmc.org
Identifying activating EGFR mutations is a useful predictive strategy that helps select a
population of advanced non-small-cell lung cancer (NSCLC) patients for treatment with …

Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations.

J Wang, B Wang, H Chu, Y Yao - OncoTargets & Therapy, 2016 - search.ebscohost.com
Identifying activating EGFR mutations is a useful predictive strategy that helps select a
population of advanced non-small-cell lung cancer (NSCLC) patients for treatment with …

Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations

J Wang, B Wang, H Chu, Y Yao - OncoTargets and Therapy, 2016 - go.gale.com
Identifying activating EGFR mutations is a useful predictive strategy that helps select a
population of advanced non-small-cell lung cancer (NSCLC) patients for treatment with …